Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19817503 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2913058 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4578041 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3424276 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12995468 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24785151 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13506359 | 0.75 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL27032882 | 0.73 | MAPT (0.49) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL11474794 | 0.73 | MAPT (0.49) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12292882 | 0.72 | MAPT (0.47) | MAPTGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | MAPT 4555/4885GRIN2D 1222/4885GRIN3B 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.